ANIK
Anika Therapeutics·NASDAQ
--
--(--)
--
--(--)
5.09 / 10
Netural
Fund flow analysis scores 7.59/10, indicating robust fund flow characteristics. Bullish trends in no significant trends contrast with bearish signals in overall, block, Small, Medium, Large, and Extra-large, suggesting positive liquidity momentum. Analyst consensus points to overwhelmingly bullish analyst consensus with strong conviction. Distribution analysis: Buy(100.0%) among 1 research opinions.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-09
InstitutionBarrington Research
Times predicted6
Historical Win Rate33.3%
What is the analyst consensus for ANIK?
- ANIK holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.09/10 (Netural).
